Longeveron Inc.
General ticker "LGVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $20.6M (TTM average)
Longeveron Inc. does not follow the US Stock Market performance with the rate: -21.9%.
Estimated limits based on current volatility of 3.6%: low 0.62$, high 0.67$
Factors to consider:
- Total employees count: 25 (+8.7%) as of 2024
- Top business risk factors: Limited operating history and no commercial products, Geopolitical risks, Operating losses and lack of profitability, Dependence on contract development and manufacturing, Regulatory and compliance
- Current price 46.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.17$, 3.86$]
- 2025-12-31 to 2026-12-31 estimated range: [1.08$, 3.52$]
Financial Metrics affecting the LGVN estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -54.01 <= 0.33
- Positive: -4.48 < Investing cash flow per share per price, % of -2.49
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LGVN quotes
Long-term LGVN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.22MM | $0.71MM | $2.39MM |
| Operating Expenses | $19.27MM | $21.74MM | $18.91MM |
| Operating Income | $-18.04MM | $-21.03MM | $-16.52MM |
| Non-Operating Income | $-0.01MM | $-0.43MM | $0.55MM |
| Interest Expense | $1.40MM | $0.00MM | $0.00MM |
| R&D Expense | $9.37MM | $9.07MM | $8.14MM |
| Income(Loss) | $-18.05MM | $-21.46MM | $-15.97MM |
| Taxes | $0.79MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-18.84MM | $-21.46MM | $-15.97MM |
| Stockholders Equity | $20.50MM | $6.74MM | $21.89MM |
| Assets | $27.41MM | $12.08MM | $25.56MM |
| Operating Cash Flow | $-13.97MM | $-19.00MM | $-13.87MM |
| Capital expenditure | $0.86MM | $0.30MM | $0.99MM |
| Investing Cash Flow | $-0.68MM | $8.19MM | $-0.64MM |
| Financing Cash Flow | $-0.51MM | $5.26MM | $28.79MM |
| Earnings Per Share** | $-8.98 | $-9.87 | $-1.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.